Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks

  1. Hui Zhao
  2. Bernard Thienpont
  3. Betül T Yesilyurt
  4. Matthieu Moisse
  5. Joke Reumers
  6. Lieve Coenegrachts
  7. Xavier Sagaert
  8. Stefanie Schrauwen
  9. Dominiek Smeets
  10. Gert Matthijs
  11. Stein Aerts
  12. Jan Cools
  13. Alex Metcalf
  14. Amanda Spurdle
  15. ANECS
  16. Frederic Amant
  17. Diether Lambrechts  Is a corresponding author
  1. VIB Vesalius Research Center, KU Leuven, Belgium
  2. University Hospital Gasthuisberg, Belgium
  3. KU Leuven, Belgium
  4. University of Leuven, Belgium
  5. Queensland Institute of Medical Research, Australia
  6. PO Royal Brisbane Hospital, Australia

Abstract

DNA replication errors that persist as mismatch mutations make up the molecular fingerprint of mismatch repair (MMR)-deficient tumors and convey them with resistance to standard therapy. Using whole-genome and -exome sequencing, we here confirm an MMR-deficient mutation signature that is distinct from other tumor genomes, but surprisingly similar to germ-line DNA, confirming that a substantial fraction of human genetic variation arises through mutations escaping MMR. Moreover, we identify a large set of recurrent indels that may serve to detect microsatellite instability (MSI). Indeed, using endometrial tumors with immunohistochemically-proven MMR deficiency, we optimize a novel marker set capable of detecting MSI and show it to have greater specificity and selectivity than standard MSI tests. Additionally, we show that recurrent indels are enriched for the 'DNA double-strand break repair by homologous recombination' pathway. Consequently, DSB repair is reduced in MMR-deficient tumors, triggering a dose-dependent sensitivity of MMR-deficient tumor cultures to DSB inducers.

Article and author information

Author details

  1. Hui Zhao

    VIB Vesalius Research Center, KU Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.
  2. Bernard Thienpont

    VIB Vesalius Research Center, KU Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.
  3. Betül T Yesilyurt

    VIB Vesalius Research Center, KU Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.
  4. Matthieu Moisse

    VIB Vesalius Research Center, KU Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.
  5. Joke Reumers

    VIB Vesalius Research Center, KU Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.
  6. Lieve Coenegrachts

    University Hospital Gasthuisberg, Leuven, Belgium
    Competing interests
    No competing interests declared.
  7. Xavier Sagaert

    University Hospital Gasthuisberg, Leuven, Belgium
    Competing interests
    No competing interests declared.
  8. Stefanie Schrauwen

    University Hospital Gasthuisberg, Leuven, Belgium
    Competing interests
    No competing interests declared.
  9. Dominiek Smeets

    VIB Vesalius Research Center, KU Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.
  10. Gert Matthijs

    KU Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.
  11. Stein Aerts

    University of Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.
  12. Jan Cools

    KU Leuven, Leuven, Belgium
    Competing interests
    No competing interests declared.
  13. Alex Metcalf

    Queensland Institute of Medical Research, Brisbane, Australia
    Competing interests
    No competing interests declared.
  14. Amanda Spurdle

    Queensland Institute of Medical Research, Brisbane, Australia
    Competing interests
    No competing interests declared.
  15. ANECS

    PO Royal Brisbane Hospital, Brisbane, Australia
    Competing interests
    No competing interests declared.
  16. Frederic Amant

    University Hospital Gasthuisberg, Leuven, Belgium
    Competing interests
    No competing interests declared.
  17. Diether Lambrechts

    VIB Vesalius Research Center, KU Leuven, Leuven, Belgium
    For correspondence
    diether.lambrechts@vib-kuleuven.be
    Competing interests
    Diether Lambrechts, an inventor on a patent application regarding the use of recurrent indels to detect MSI. The VIB is owner of this patent application, and the said patent application has been licensed to an outside company. Neither VIB nor any of the authors have equity stakes in the company. However, VIB stands to eventually receive royalties.

Ethics

Human subjects: Informed consent and consent to publish was obtained from all patients. Ethical approval was obtained at the ethical committee of University Hospital Gasthuisberg of Leuven with identifier ML2266.

Copyright

© 2014, Zhao et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 6,369
    views
  • 1,023
    downloads
  • 70
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Hui Zhao
  2. Bernard Thienpont
  3. Betül T Yesilyurt
  4. Matthieu Moisse
  5. Joke Reumers
  6. Lieve Coenegrachts
  7. Xavier Sagaert
  8. Stefanie Schrauwen
  9. Dominiek Smeets
  10. Gert Matthijs
  11. Stein Aerts
  12. Jan Cools
  13. Alex Metcalf
  14. Amanda Spurdle
  15. ANECS
  16. Frederic Amant
  17. Diether Lambrechts
(2014)
Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks
eLife 3:e02725.
https://doi.org/10.7554/eLife.02725

Share this article

https://doi.org/10.7554/eLife.02725

Further reading

    1. Developmental Biology
    2. Genetics and Genomics
    Ignacy Czajewski, Bijayalaxmi Swain ... Daan MF van Aalten
    Research Article

    O-GlcNAcylation is an essential intracellular protein modification mediated by O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). Recently, missense mutations in OGT have been linked to intellectual disability, indicating that this modification is important for the development and functioning of the nervous system. However, the processes that are most sensitive to perturbations in O-GlcNAcylation remain to be identified. Here, we uncover quantifiable phenotypes in the fruit fly Drosophila melanogaster carrying a patient-derived OGT mutation in the catalytic domain. Hypo-O-GlcNAcylation leads to defects in synaptogenesis and reduced sleep stability. Both these phenotypes can be partially rescued by genetically or chemically targeting OGA, suggesting that a balance of OGT/OGA activity is required for normal neuronal development and function.

    1. Evolutionary Biology
    2. Genetics and Genomics
    Michael James Chambers, Sophia B Scobell, Meru J Sadhu
    Research Article

    Evolutionary arms races can arise at the contact surfaces between host and viral proteins, producing dynamic spaces in which genetic variants are continually pursued.  However, the sampling of genetic variation must be balanced with the need to maintain protein function. A striking case is given by protein kinase R (PKR), a member of the mammalian innate immune system. PKR detects viral replication within the host cell and halts protein synthesis to prevent viral replication by phosphorylating eIF2α, a component of the translation initiation machinery. PKR is targeted by many viral antagonists, including poxvirus pseudosubstrate antagonists that mimic the natural substrate, eIF2α, and inhibit PKR activity. Remarkably, PKR has several rapidly evolving residues at this interface, suggesting it is engaging in an evolutionary arms race, despite the surface’s critical role in phosphorylating eIF2α. To systematically explore the evolutionary opportunities available at this dynamic interface, we generated and characterized a library of 426 SNP-accessible nonsynonymous variants of human PKR for their ability to escape inhibition by the model pseudosubstrate inhibitor K3, encoded by the vaccinia virus gene K3L. We identified key sites in the PKR kinase domain that harbor K3-resistant variants, as well as critical sites where variation leads to loss of function. We find K3-resistant variants are readily available throughout the interface and are enriched at sites under positive selection. Moreover, variants beneficial against K3 were also beneficial against an enhanced variant of K3, indicating resilience to viral adaptation. Overall, we find that the eIF2α-binding surface of PKR is highly malleable, potentiating its evolutionary ability to combat viral inhibition.